Phospho-SNAI1 (S246) Antibody

What is SNAI1 and what is the significance of its phosphorylation at S246?

SNAI1 (Snail family transcriptional repressor 1), also known as Zinc finger protein SNAI1 or Protein snail homolog 1, is a transcriptional repressor critically involved in epithelial-to-mesenchymal transition (EMT), embryonic mesoderm formation, growth arrest, survival, and cell migration . With a molecular weight of approximately 29 kDa, SNAI1 functions by binding to E-boxes of gene promoters (including E-cadherin/CDH1, CLDN7, and KRT8) and recruiting histone demethylase KDM1A to repress transcription .

Phosphorylation at serine 246 (S246) represents a specific post-translational modification that regulates SNAI1 activity. This phosphorylation site is located within the amino acid sequence context T-F-SP-R-M . Detecting this specific phosphorylation event allows researchers to investigate regulatory mechanisms controlling SNAI1 function in diverse cellular processes, particularly in cancer progression and development.

What are the typical applications for Phospho-SNAI1 (S246) Antibody in research settings?

Phospho-SNAI1 (S246) antibodies are validated for multiple research applications:

These antibodies are specifically engineered to detect endogenous levels of SNAI1 protein only when phosphorylated at S246, enabling precise monitoring of this post-translational modification in experimental contexts .

What species reactivity can be expected with commercially available Phospho-SNAI1 (S246) Antibodies?

Available Phospho-SNAI1 (S246) antibodies show cross-reactivity with multiple species:

Researchers should verify specific cross-reactivity when working with species other than human or mouse, as validation data may be limited for some commercial antibodies .

How do different experimental conditions affect Phospho-SNAI1 (S246) detection?

Detection of phosphorylated SNAI1 at S246 is highly sensitive to experimental conditions:

• Fixation methods: Phospho-epitopes can be particularly sensitive to over-fixation. For immunohistochemistry, optimal results are typically achieved with 10% neutral buffered formalin fixation for 24-48 hours. Extended fixation periods may mask the phospho-epitope .

• Sample preparation: Phosphorylation states can rapidly change during sample handling. Extraction buffers should contain phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) to preserve phosphorylation status .

• Storage conditions: Antibody performance remains optimal when stored as recommended at -20°C, with aliquoting to avoid repeated freeze/thaw cycles that may degrade antibody quality .

• Cell treatment: Phosphorylation at S246 may be enhanced in certain contexts, such as cancer cell lines or under specific growth factor stimulation conditions. Researchers should consider including appropriate positive controls when establishing detection protocols .

What methodological approaches can validate the specificity of Phospho-SNAI1 (S246) Antibody?

Multiple validation strategies should be employed to confirm antibody specificity:

• Competing peptide assay: Preincubation with the immunizing phosphopeptide should abolish signal in Western blot. This is demonstrated in several antibody validation studies, where signal disappears in the presence of the immunizing peptide .

• Phosphatase treatment: Sample treatment with lambda phosphatase should eliminate recognition by the phospho-specific antibody while leaving detection by total SNAI1 antibody intact.

• Knockout/knockdown validation: Comparing signals between wild-type and SNAI1 knockout/knockdown samples provides strong validation of specificity.

• Site-directed mutagenesis: Comparing detection between wild-type SNAI1 and S246A mutant (preventing phosphorylation) confirms phospho-specificity.

• Cross-reactivity assessment: Western blot testing with both SNAI1 and SNAI2 (SLUG) recombinant proteins has confirmed that some antibodies recognize both proteins when phosphorylated, as demonstrated in ab63568 validation experiments .

How does phosphorylation at S246 impact SNAI1's functional role in EMT and cancer progression?

Serine 246 phosphorylation represents a critical regulatory mechanism for SNAI1:

• Protein stability regulation: Phosphorylation at S246 may influence SNAI1 protein stability and nuclear localization, affecting its ability to repress target genes.

• EMT regulation: As SNAI1 is a master regulator of EMT, phosphorylation at S246 may modulate its interaction with E-cadherin promoter elements and other EMT-related genes .

• Cancer implications: Elevated phospho-SNAI1 (S246) levels have been detected in various cancer types, particularly in breast carcinoma tissues as demonstrated by immunohistochemical studies .

• Signaling pathway integration: Phosphorylation at S246 likely integrates signals from upstream kinases that regulate SNAI1 activity in response to environmental cues and cellular stress.

Research investigating the kinases responsible for S246 phosphorylation and the downstream consequences of this modification remains an active area of investigation in cancer biology and development.

What are the optimal Western blot conditions for detecting Phospho-SNAI1 (S246)?

Western blot detection of Phospho-SNAI1 (S246) requires careful optimization:

Researchers should note that observed band sizes may vary slightly from the predicted 29 kDa, with some reports of bands at 26 kDa or 68 kDa for tagged recombinant proteins .

What controls are essential when working with Phospho-SNAI1 (S246) Antibody?

Several controls are critical for reliable interpretation of Phospho-SNAI1 (S246) data:

• Positive control: Use of cell lines known to express phosphorylated SNAI1, such as MCF-7, HT29, or A549 cell lysates .

• Phosphopeptide competition: Running parallel samples with and without pre-incubation with the immunizing phosphopeptide demonstrates specificity, as demonstrated in validation studies where signal is eliminated in peptide-competed samples .

• Total SNAI1 detection: Parallel blots with antibodies detecting total SNAI1 (regardless of phosphorylation state) help interpret phosphorylation levels relative to total protein expression .

• Loading control: Standard loading controls such as beta-actin or GAPDH ensure equal protein loading across samples.

• Molecular weight markers: Precise molecular weight markers help distinguish specific SNAI1 bands (expected around 29 kDa) from non-specific signals .

How should researchers optimize immunohistochemistry protocols for Phospho-SNAI1 (S246) detection in tissue samples?

Optimization of IHC protocols for phospho-epitopes requires special considerations:

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) is typically most effective for phospho-epitopes. Optimization may be necessary for different tissue types.

• Blocking endogenous phosphatases: Include phosphatase inhibitors in wash buffers to prevent dephosphorylation during processing.

• Antibody validation in tissues: Validation in positive control tissues, such as breast carcinoma samples where SNAI1 phosphorylation has been confirmed, is essential .

• Counterstaining optimization: Careful optimization of counterstaining intensity ensures visualization of phospho-SNAI1 signal, which may be relatively weak compared to some other nuclear markers.

• Signal amplification: For low-abundance phospho-proteins, signal amplification systems like tyramide signal amplification may enhance detection sensitivity.

Researchers should note that nuclear localization of phospho-SNAI1 is expected, and cytoplasmic staining should be carefully evaluated for specificity .

How can researchers address non-specific binding when using Phospho-SNAI1 (S246) Antibody?

Several strategies can mitigate non-specific binding:

• Antibody dilution optimization: Testing a range of antibody dilutions (1:500-1:3000 for WB) identifies the optimal concentration that maximizes specific signal while minimizing background .

• Blocking optimization: Testing different blocking agents (BSA vs. non-fat milk) and concentrations (3-5%) can improve signal-to-noise ratio.

• Wash stringency: Increasing the concentration of Tween-20 in wash buffers (0.1% to 0.3%) and extending wash times can reduce non-specific binding.

• Preabsorption with recombinant protein: For particularly problematic samples, preabsorbing the antibody with recombinant non-phosphorylated SNAI1 can enhance phospho-specificity.

• Cross-reactivity assessment: Be aware that some phospho-SNAI1 (S246) antibodies may cross-react with SNAI2 (SLUG) due to sequence homology around the phosphorylation site .

What factors might contribute to variability in Phospho-SNAI1 (S246) detection across different experimental systems?

Several factors can lead to experimental variability:

• Cell line differences: SNAI1 expression and phosphorylation levels vary significantly across cell lines. Western blot validation data shows variable detection across A431, HepG2, A549, PC-3, K562, SW620, and Raji cell lines .

• Growth conditions: Cell density, serum starvation, and growth factor stimulation can dramatically alter phosphorylation states.

• Tissue preservation methods: For tissue samples, the time from excision to fixation critically affects phospho-epitope preservation.

• Antibody lot-to-lot variability: Polyclonal antibodies may show greater lot-to-lot variation than monoclonal antibodies in detecting phospho-epitopes.

• Sample preparation timing: Rapid dephosphorylation can occur during sample handling; standardizing the time from cell lysis to protein denaturation is crucial for reproducible results.

• Detection system sensitivity: Different ECL systems vary in sensitivity and may affect the ability to detect low-abundance phospho-proteins.

How should researchers interpret discrepancies between results obtained using phospho-specific versus total SNAI1 antibodies?

Discrepancies between phospho-specific and total SNAI1 detection require careful interpretation:

• Phosphorylation state changes: Changes in phospho-SNAI1 signal without corresponding changes in total SNAI1 suggest regulation at the post-translational level rather than expression level.

• Antibody epitope accessibility: Structural changes due to phosphorylation may affect epitope accessibility for total SNAI1 antibodies in some applications.

• Subcellular localization differences: Phosphorylation may alter SNAI1 subcellular localization, potentially explaining differences in detection patterns between phospho-specific and total antibodies in cellular imaging applications.

• Protein complex formation: Phosphorylation can mediate protein-protein interactions that might mask epitopes recognized by total SNAI1 antibodies.

• Degradation pathway activation: Phosphorylation may target SNAI1 for degradation, resulting in reduced detection of phosphorylated forms despite unchanged total protein levels.

Researchers should systematically evaluate these possibilities through complementary approaches such as subcellular fractionation, immunoprecipitation, and phosphatase treatment experiments.

How can Phospho-SNAI1 (S246) Antibody be utilized in multiplexed detection systems?

Multiplexed detection approaches with Phospho-SNAI1 (S246) can provide contextual data:

• Multi-color immunofluorescence: Combining Phospho-SNAI1 (S246) antibody with markers of EMT (E-cadherin, Vimentin) or cell signaling pathway components provides insight into regulatory relationships.

• Phospho-protein arrays: Integration of Phospho-SNAI1 (S246) detection into phospho-protein arrays enables simultaneous analysis of multiple signaling pathways.

• Mass cytometry (CyTOF): Metal-conjugated Phospho-SNAI1 (S246) antibodies can be incorporated into high-dimensional single-cell analyses for heterogeneity assessment.

• Sequential immunostaining: For tissue sections, sequential detection of phospho and total SNAI1 on the same section provides direct comparison of phosphorylation states at the single-cell level.

Researchers should validate antibody performance in each multiplexed system, as antibody behavior may differ from standard single-marker applications.

What methodological approaches can quantify the ratio of phosphorylated to total SNAI1 protein?

Accurate quantification of phosphorylation ratios requires specialized techniques:

• Sequential immunoblotting: Stripping and reprobing membranes with phospho-specific followed by total SNAI1 antibodies, with careful validation of stripping efficiency.

• Parallel gel analysis: Running identical samples on parallel gels for phospho and total detection eliminates concerns about incomplete stripping.

• Two-color Western blot: Using species-different phospho and total antibodies with spectrally distinct secondary antibodies for simultaneous detection.

• Phospho-protein ELISA: Specialized ELISA formats that capture total protein and detect the phosphorylated fraction.

• Mass spectrometry: Absolute quantification of phosphorylated and non-phosphorylated peptides containing the S246 site provides the most accurate ratio determination.

Whichever method is chosen, standard curves using recombinant phosphorylated and non-phosphorylated SNAI1 should be considered for accurate quantification.

How might Phospho-SNAI1 (S246) analysis be integrated into studies of tumor heterogeneity and treatment resistance?

Phospho-SNAI1 (S246) analysis can provide critical insights in cancer research:

• Single-cell analysis: Techniques like imaging mass cytometry or multiplex immunofluorescence with Phospho-SNAI1 (S246) antibodies can map EMT heterogeneity within tumors.

• Patient-derived models: Monitoring Phospho-SNAI1 (S246) in patient-derived xenografts or organoids before and after treatment can identify EMT-mediated resistance mechanisms.

• Liquid biopsy integration: Developing protocols to detect Phospho-SNAI1 (S246) in circulating tumor cells may provide real-time monitoring of EMT states during treatment.

• Kinase inhibitor screens: Systematic testing of kinase inhibitor panels to identify regulators of SNAI1 S246 phosphorylation could reveal new therapeutic targets.

• Immunotherapy response correlation: Analysis of Phospho-SNAI1 (S246) patterns in pre-treatment biopsies might predict immunotherapy response, as EMT status influences immune cell interactions.

These advanced applications represent emerging research directions where Phospho-SNAI1 (S246) antibodies could provide unique insights into cancer biology and treatment response.